Table 20
In this guide
In this guideOn this page
Skip the menu of subheadings on this page.This is a paper for discussion. This does not represent the views of the Committee and should not be cited.
Table 20. Developmental toxicity studies for PFCAs - PFBA
*Derived by contractor; ** calculated according to EFSA. (2012); NR – not reported; NA – not applicable.
|
Substance / CAS no. / purity / reference |
Strain & species / sex / no. of animals |
Dose (mg/kg bw/day) / vehicle / route of admin / duration / Guideline (GL) study / Good Laboratory Practice (GLP) status |
PFAS concentration (µg/mL / µg/g) |
Observed effects at LOAEL (controls vs treated groups) Recovery (controls vs treated groups) |
Published NOAEL / LOAEL (mg/kg bw/day) |
Study author comments |
Comments |
PFBA ammonium saltCAS No. not given 98%. Das et al. (2008) |
Pregnant CD-1 mice. Female 5/dose. Recovery group: 5/dose. |
0, 35, 175 or 350, Water, Gavage, GD1-GD17, Non-GL study, GLP not stated. Recovery group: 0, 35, 175 or 350, GD1-GD18, PND22.
|
At 35 mg/kg bw/day (mean ± SE) Serum: 3.78 ± 1.01 Liver: 1.41 ± 0.42. At 175 mg/kg bw/day Serum: 4.44 ± 0.65 Liver: 1.60 ± 0.25.
|
Maternal effects ↑ liver weight (data only reported in figures). Recovery: Maternal effects Liver weight comparable to controls after 3 weeks (data NR).
|
Maternal: 35 / 175* Recovery: Maternal: 35 / 175*
|
Findings reflect a general hepatic response to PFBA in the mouse and also indicate indirectly an effective transplacental transfer of the chemical from the maternal compartment to the foetuses, leading to similar liver enlargement. |
K2 The study investigated if PFBA elicited adverse effects similar to PFOS and PFOA in mice. Limited endpoints related to liver were measured. Expression of ‘hepatic genes’ were not significantly altered in neonatal liver. Study was funded by U.S. Environmental Protection Agency. |